Hengrui Medicine Grants Merck Sharp & Dohme Rights to Market Cardiovascular Drug; Shares Up 4%

MT Newswires Live
03-26

Jiangsu Hengrui Medicine (SHA:600276) granted US-based pharmaceutical giant Merck Sharp & Dohme the license for the HRS-5346 drug for $200 million, according to a Shanghai Stock Exchange filing on Tuesday.

Merck Sharp & Dohme will be given the rights to develop, manufacture, and commercialize the drug globally. The drug, which is currently undergoing phase II clinical trials in China, is used to treat cardiovascular diseases.

As part of the agreement, the Chinese medicine maker will receive milestone payments of up to $1.77 billion and royalties from sales outside the Greater China region, the filing said.

Hengrui's shares jumped less than 4% in recent trade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10